Department of Otorhinolaryngology, Sağlik Bilimleri University Ankara Traning and Research Hospital, Ankara.
Department of Pathology, Faculty of Veterinary Medicine, Harran University, Şanliurfa, Turkey.
Otol Neurotol. 2021 Jun 1;42(5):e568-e572. doi: 10.1097/MAO.0000000000003061.
We hypothesized that oral montelukast treatment could inhibit cholesteatoma formation in an experimental animal model.
Inflammation and excessive proliferation have been described in the histopathology of cholesteatoma. The aim of this study was to determine the effect of oral montelukast on cholesteatoma development.
Eighteen healthy female Wistar albino rats weighing 250 g were chosen for the study. The animals were divided into two groups: group 1 received montelukast and group 2 was the control group. Intratympanic propylene glycol injection was administered into the left ears and physiologic serum was instilled into the right ears of the animals on the first, eighth, and fifteenth days. The effects of montelukast administration were evaluated by histological examination of the tympanic membrane and middle ear.
Group 1 (montelukast group) showed significant differences in terms of cholesteatoma formation, granulation, epithelial invagination, and inflammation. Cholesteatoma formation in the left ear was observed in 2 (22%) and 8 (89%) rats in groups 1 and 2, respectively (p = 0.015).
Development of cholesteatoma and inflammation was significantly lower in the montelukast-administered group. Thus, oral montelukast was found effective in preventing cholesteatoma formation.
我们假设口服孟鲁司特治疗可以抑制实验动物模型中的胆脂瘤形成。
在胆脂瘤的组织病理学中已经描述了炎症和过度增殖。本研究的目的是确定口服孟鲁司特对胆脂瘤发展的影响。
选择了 18 只体重为 250g 的健康雌性 Wistar 白化大鼠进行研究。动物分为两组：第 1 组接受孟鲁司特，第 2 组为对照组。在第 1、8 和 15 天，将丙二醇注入动物的左耳，将生理血清注入右耳。通过对鼓膜和中耳的组织学检查来评估孟鲁司特给药的效果。
第 1 组（孟鲁司特组）在胆脂瘤形成、肉芽组织、上皮内陷和炎症方面表现出显著差异。第 1 组（孟鲁司特组）和第 2 组（对照组）的左耳胆脂瘤形成分别为 2 只（22%）和 8 只（89%）（p=0.015）。
在给予孟鲁司特的组中，胆脂瘤和炎症的发展明显较低。因此，口服孟鲁司特被发现对预防胆脂瘤形成有效。
